Navigation Links
Watson Pharmaceuticals and Elan Settle Lawsuit Over Naproxen Sodium
Date:3/6/2009

CORONA, Calif., March 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that it has reached a settlement with Elan Corporation, Plc on outstanding patent litigation related to Watson's generic version of Naprelan(R) (naproxen sodium) tablets.

Under the terms of the agreement, Watson will pay Elan $18 million in full settlement of all disputes related to Watson's development, manufacturing, marketing and sale of its naproxen sodium product. Watson also has agreed not to market or sell its naproxen sodium product until the expiration or final finding of invalidity or unenforceability of U.S. Patent No. 5,637,320. Other details concerning the settlement have not been disclosed.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes generic and specialty brand pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.

For press releases and other company information, visit Watson Pharmaceutical's Web site at http://www.watson.com.

Watson's Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, risks that resolution of patent infringement litigation through settlement could result in investigations or actions by private parties or government authorities, including the U.S. Department of Justice and /or the Federal Trade Commission; the difficulty of predicting the timing or outcome of litigation related to patent infringement; the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2008.

Naprelan(R) is a registered trademark of Elan Corporation, Plc

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook
2. Watson Acknowledges Federal Trade Commission Action Regarding AndroGel Patent Settlement
3. Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation
4. Watson Pharmaceuticals Receives FDA Approval for Mint Coated Nicotine Gum
5. Watson Pharmaceuticals Receives FDA Final Approval for Generic Mircette(R)
6. U.S. Workers Taking Steps to Lower Medical Costs, Watson Wyatt Survey Finds
7. China Shenghuo Announces Additional Roll-Out of 12 Ways Cosmetics Products to Watsons Stores
8. Driving Consumer Engagement Is Focus of Address by Healthfitness Chief Medical Officer at Watson Wyatt Health Care Solutions Event
9. Watson Pharmaceuticals Receives FDA Final Approval for Generic Wellbutrin XL(R) 150 mg
10. Watson Enters Into Agreement to Acquire Products Related to Tevas Proposed Acquisition of Barr
11. Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... , ... February 28, 2017 , ... Las Vegas Skin ... South Rancho location on Friday, March 10, 2017, 4-7 pm PST. For more than ... this clinic, located in the South Rancho neighborhood, has been renovated to provide medical ...
(Date:2/28/2017)... , ... February 28, 2017 , ... ... decade, has challenges as they transition from military to civilian life. Body image ... two million who experience poorer health and greater occurrence of chronic mental health ...
(Date:2/27/2017)... Houston, Texas (PRWEB) , ... February 27, 2017 ... ... leader in the alternative health care industry, announces Chris Brandl as its New ... has brought vision and purpose to corporations throughout his career. He began his ...
(Date:2/27/2017)... ... , ... The threat of nuclear warfare has long plagued this world. In ... underground testing of nuclear weapons. Years later, when her co-workers began dying, Dot started ... Nuclear Testing,” Clayton exposes the critical decisions made by agencies involved in the nuclear ...
(Date:2/27/2017)... ... February 26, 2017 , ... Miro is the ultimate ... and video system brings songs, movies, TV shows and much more apps for user ... high-definition sound. An immersive view of 1280 x 720 provides crisp images with remarkable ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... Feb. 27, 2017 Pulmonary drug delivery market ... from USD 36.10 billion in 2016, at a CAGR ... pulmonary route as an alternate route of drug delivery, ... increasing incidence of respiratory diseases such as COPD, asthma, ... growth during the forecast period. However, emerging markets and ...
(Date:2/28/2017)... -- Clarivate Analytics marks the passing of one if its founding fathers, Dr. ... science in the service of scientific and scholarly research. A pioneer in ... that revolutionized the way researchers work with the literature, Garfield passed away ... ... Dr. Eugene Garfield, ...
(Date:2/28/2017)... Research and Markets has announced the addition of the ... their offering. ... The global digestive enzyme supplements market is expected ... regarding the severity of digestive disorders coupled with the need ... the forecast period. The increasing incidence of gastrointestinal tract diseases, ...
Breaking Medicine Technology: